CAJ | 학술논문

目的:探讨食管小细胞癌综合治疗的最佳模式.方法:回顾性分析了51例初始治疗采用化疗为基础综合治疗的食管小细胞癌患者临床资料,比较手术+化疗、放疗+化疗和手术+放疗+化疗三组患者生存期的差异.结果:手术+化疗组29例,放疗+化疗组16例,手术+放疗+化疗组6例.全组患者中位生存期为13.6个月,1、2、3年生存率为56.5%、22.4%、9.6%.三组患者在性别、年龄、病理类型、病灶部位、长度及化疗疗程上分布无差异(P>0.05),放疗+化疗组包含有更多的广泛期患者(P<0.05).中位生存期在手术+化疗组患者为13.3个月,放疗+化疗组13.1个月,手术+放疗+化疗组14.2个月,三组患者生存期未见差异(P=0.626).结论:放疗联合化疗是食管小细胞癌有效治疗模式,放化疗可以取得和手术联合化疗相似的生存获益.
목적:탐토식관소세포암종합치료적최가모식.방법:회고성분석료51례초시치료채용화료위기출종합치료적식관소세포암환자림상자료,비교수술+화료、방료+화료화수술+방료+화료삼조환자생존기적차이.결과:수술+화료조29례,방료+화료조16례,수술+방료+화료조6례.전조환자중위생존기위13.6개월,1、2、3년생존솔위56.5%、22.4%、9.6%.삼조환자재성별、년령、병리류형、병조부위、장도급화료료정상분포무차이(P>0.05),방료+화료조포함유경다적엄범기환자(P<0.05).중위생존기재수술+화료조환자위13.3개월,방료+화료조13.1개월,수술+방료+화료조14.2개월,삼조환자생존기미견차이(P=0.626).결론:방료연합화료시식관소세포암유효치료모식,방화료가이취득화수술연합화료상사적생존획익.
Objective: To investigate the optimal model of comprehensive therapy for small-cell esophageal carcinoma (SCEC). Methods: The clinical data of 51 SCEC patients who underwent chemotherapy-based comprehensive treatment as the first line of treatment was analyzed retrospectively. We compared the median survival time (MST) of patients among the surgery plus chemotherapy group (S+C), chemoradiotherapy group (R+C), and surgery plus chemoradiotherapy group (S+R+C). Results: The S+C, R+C, and S+R+C groups comprised 29, 16, and 6 cases, respectively. The MST of the 51 patients was 13.6 months, and the one-, two- and three-year survival rates were 56.5%, 22.4%, and 9.6%, respectively. No significant difference in the distribution of clinical characteristics was found among the three groups (P>0.05). The R+C group contained more cases in the extensive stage (P<0.05). The MST of the S+C, R+C, and S+R+C groups were 13.3, 13.1, and 14.2 months, respectively, with no significant difference (P=0.626). Conclusion: Chemoradiotherapy is an effective way of treating SCEC; it can achieve similar survival benefits as surgery plus chemotherapy.